Elcatonin is a physio-chemically stable calcitonin derivative in which the disulfide bond between cysteine residues at positions 1 and 7 of eel calcitonin has been replaced by an ethylene bond. The primary pharmacological effect of Elcatonin is its activity at specific osteoclast receptors, resulting in diminished osteoclast activity at extremely low concentrations. Elcatonin inhibits the bones autolysis and renal calcium, phosphorus, and sodium reabsorption thus keeps blood calcium at a normal level. In clinical settings, once-weekly intramuscular injection of elcatonin has been shown to significantly increase bone mineral density within 6 months and to alleviate post-fracture pain and improve Quality of life in osteoporosis

Dasiglucagon (Zegalogue®) is an antihypoglycaemic agent being developed by Zealand Pharma for the treatment of hypoglycaemia, type 1 diabetes mellitus (T1DM) management and congenital hyperinsulinism. Dasiglucagon is a glucagon receptor agonist, which increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for dasiglucagon to produce an antihypoglycemic effect. In March 2021, dasiglucagon received its first approval in the USA for the treatment of severe hypoglycaemia in paediatric and adult patients with diabetes aged 6 years and above. Dasiglucagon, a glucagon analogue, is available as a single-dose autoinjector or prefilled syringe for subcutaneous injection.

Abaloparatide (brand name Tymlos) is a human parathyroid hormone related peptide [PTHrP(1-34)] analog indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Abaloparatide is a PTHrP(1-34) analog which acts as an agonist at the PTH1 receptor (PTH1R). This results in activation of the cAMP signaling pathway in target cells. In rats and monkeys, abaloparatide had an anabolic effect on bone, demonstrated by increases in BMD and bone mineral content (BMC) that correlated with increases in bone strength at vertebral and/or nonvertebral sites. Abaloparatide was approved in April 28, 2017 by the FDA (as Tymlos) for the treatment of postmenopausal women with osteoporosis at high risk for fracture.